{
    "clinical_study": {
        "@rank": "158081", 
        "arm_group": [
            {
                "arm_group_label": "Healthy Volunteers", 
                "arm_group_type": "Experimental", 
                "description": "single dose of NBI-98854 50 mg capsule"
            }, 
            {
                "arm_group_label": "Mild Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "single dose of NBI-98854 50 mg capsule"
            }, 
            {
                "arm_group_label": "Moderate Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "single dose of NBI-98854 50 mg capsule"
            }, 
            {
                "arm_group_label": "Severe Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "single dose of NBI-98854 50 mg capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to: test the safety, tolerability, and\n      pharmacokinetics (PK testing, the study of how the body absorbs, distributes, breaks down\n      and eliminates a drug) of a single dose of the investigational study drug NBI-98854 in\n      subjects with normal hepatic function or mild, moderate, or severe hepatic impairment."
        }, 
        "brief_title": "Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects", 
        "condition_browse": {
            "mesh_term": "Hepatic Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18 to 75 years of age.\n\n          -  Healthy volunteers must be in good general health.\n\n          -  Subjects with hepatic impairment must be judged to be in stable condition.\n\n          -  Subjects of childbearing potential must agree to use hormonal or two forms of\n             nonhormonal birth control during the study.\n\n          -  Female subjects must not be pregnant, given birth within 1 year of study start, or\n             breastfeeding.\n\n          -  Have a body mass index (BMI) of 18 to 40 kg/m2 (both inclusive).\n\n        Exclusion Criteria:\n\n          -  Report more than two alcoholic beverages daily or more than 14 alcoholic beverages\n             weekly withing 7 days of study start.\n\n          -  Have a known history of neuroleptic malignant syndrome.\n\n          -  Have a positive human immunodeficiency virus (HIV) antibody result at screening or\n             have a history of positive result.\n\n          -  Have received an investigational drug within 30 days before screening or plan to use\n             an investigational drug (other than NBI-98854) during the study.\n\n          -  Have an allergy, hypersensitivity, or intolerance to tetrabenazine.\n\n          -  Had a blood loss greater than or equal to 500 mL or donated blood within 56 days of\n             study start.\n\n          -  Have had previous exposure with NBI-98854."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916993", 
            "org_study_id": "NBI-98854-1303"
        }, 
        "intervention": {
            "arm_group_label": [
                "Healthy Volunteers", 
                "Mild Hepatic Impairment", 
                "Moderate Hepatic Impairment", 
                "Severe Hepatic Impairment"
            ], 
            "intervention_name": "NBI-98854 50 mg capsule", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80228"
                    }, 
                    "name": "DaVita Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Davita Clinical Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency", 
        "overall_official": {
            "affiliation": "Neurocrine Biosciences", 
            "last_name": "Chris O'Brien, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Evaluation of plasma concentrations of NBI-98854 and metabolites following administration of NBI-98854", 
                "safety_issue": "No", 
                "time_frame": "45 minutes prior to NBI-98854 dosing, and 15, 30, 45 minutes, and 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose"
            }, 
            {
                "measure": "Number of Participants with Adverse Events following dosing with NBI-98854", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916993"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Neurocrine Biosciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neurocrine Biosciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}